Literature DB >> 20102705

Erythropoietin-induced neuroprotection requires cystine glutamate exchanger activity.

Brian Sims1, Melinda Clarke, Wilfred Njah, E'lana Shuford Hopkins, Harald Sontheimer.   

Abstract

Erythropoietin (Epo) has been used for many years in neonates for the treatment of anemia of prematurity. Epo has also been proposed for treatment of neonatal brain injury, as mounting evidence suggests neuroprotective properties for Epo. However, Epo's neuroprotective mechanism of action is poorly understood. In this study we hypothesized that Epo may confer neuroprotection by enhancing cellular redox defense brought about by cellular glutathione (GSH). This was examined in cultures of differentiated cortical neural stem cells and using the B104 cell line as model systems. Our data shows that Epo causes a time- and dose-dependent increase in expression and activity of system Xc(-), the transporter responsible for uptake of cystine for the production of glutathione. Cystine uptake increases 3-5 fold in differentiated neural stem cells and B104 cells treated with Epo. Exposure of cells to 100 microM kainate suppressed cellular GSH and caused excitotoxicity, but GSH levels and cell viability were completely restored by Epo in the continued presence of kainate. This rescue effect of Epo vanished if system Xc(-) was inhibited pharmacologically using S4-CPG in the presence of Epo leading to marked cell death of B104 cells and cultured mouse cortical neural stem cells. This could also be achieved using xCT siRNA to decrease xCT expression. This data suggests that system Xc(-) activity and protein expression are positively regulated by Epo directly explaining its neuroprotective effect. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102705      PMCID: PMC2840049          DOI: 10.1016/j.brainres.2010.01.040

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  34 in total

Review 1.  The brain erythropoietin system and its potential for therapeutic exploitation in brain disease.

Authors:  Martin Hasselblatt; Hannelore Ehrenreich; Anna-Leena Sirén
Journal:  J Neurosurg Anesthesiol       Date:  2006-04       Impact factor: 3.956

2.  Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats.

Authors:  Augusto Sola; Marta Rogido; Ben H Lee; Tom Genetta; Tong-Chun Wen
Journal:  Pediatr Res       Date:  2005-02-17       Impact factor: 3.756

3.  The 4F2 antigen heavy chain induces uptake of neutral and dibasic amino acids in Xenopus oocytes.

Authors:  R G Wells; W S Lee; Y Kanai; J M Leiden; M A Hediger
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

4.  Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation.

Authors:  Andy Y Shih; Heidi Erb; Xiaojian Sun; Shigenobu Toda; Peter W Kalivas; Timothy H Murphy
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

5.  Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin.

Authors:  Jing Liu; Purnima Narasimhan; Fengshan Yu; Pak H Chan
Journal:  Stroke       Date:  2005-05-12       Impact factor: 7.914

6.  Inhibition of cystine uptake disrupts the growth of primary brain tumors.

Authors:  Wook Joon Chung; Susan A Lyons; Gina M Nelson; Hashir Hamza; Candece L Gladson; G Yancey Gillespie; Harald Sontheimer
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

Review 7.  Erythropoietin and the anaemia of chronic disease.

Authors:  S B Krantz
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

8.  Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion.

Authors:  S A Back; X Gan; Y Li; P A Rosenberg; J J Volpe
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

9.  Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis.

Authors:  M Uppenkamp; E Makarova; S Petrasch; G Brittinger
Journal:  Ann Hematol       Date:  1998-11       Impact factor: 3.673

10.  Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.

Authors:  D Ribatti; P L Poliani; V Longo; D Mangieri; B Nico; A Vacca
Journal:  Histopathology       Date:  2007-04       Impact factor: 5.087

View more
  10 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  The transient receptor potential (TRP) channel TRPC3 TRP domain and AMP-activated protein kinase binding site are required for TRPC3 activation by erythropoietin.

Authors:  Iwona Hirschler-Laszkiewicz; Qin Tong; Kathleen Waybill; Kathleen Conrad; Kerry Keefer; Wenyi Zhang; Shu-jen Chen; Joseph Y Cheung; Barbara A Miller
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

3.  Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.

Authors:  Katja Linher-Melville; Sina Haftchenary; Patrick Gunning; Gurmit Singh
Journal:  Mol Cell Biochem       Date:  2015-04-21       Impact factor: 3.396

4.  Trpc2 depletion protects red blood cells from oxidative stress-induced hemolysis.

Authors:  Iwona Hirschler-Laszkiewicz; Wenyi Zhang; Kerry Keefer; Kathleen Conrad; Qin Tong; Shu-jen Chen; Sarah Bronson; Joseph Y Cheung; Barbara A Miller
Journal:  Exp Hematol       Date:  2011-09-14       Impact factor: 3.084

5.  Long-term moderate dose exogenous erythropoietin treatment protects from intermittent hypoxia-induced spatial learning deficits and hippocampal oxidative stress in young rats.

Authors:  Jobran M Al-Qahtani; Basel A Abdel-Wahab; Samy M Abd El-Aziz
Journal:  Neurochem Res       Date:  2013-11-20       Impact factor: 3.996

6.  Does erythropoietin affect the outcome and complication rates of patient with traumatic brain injury? A pooled-analysis.

Authors:  Yuping Li; Jun Zhang; Haili Wang; Lei Zhu; Hengzhu Zhang; Qiang Ma; Xiaoguang Liu; Lun Dong; Guangyu Lu
Journal:  Neurol Sci       Date:  2022-01-19       Impact factor: 3.307

7.  Regulation of System xc(-) by Pharmacological Manipulation of Cellular Thiols.

Authors:  Rebecca Albano; Nicholas J Raddatz; Julie Hjelmhaug; David A Baker; Doug Lobner
Journal:  Oxid Med Cell Longev       Date:  2015-04-09       Impact factor: 6.543

8.  Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum.

Authors:  Iraj Ragerdi Kashani; Hossein Chavoshi; Parichehr Pasbakhsh; Mahmoud Hassani; Ameneh Omidi; Reza Mahmoudi; Cordian Beyer; Adib Zendedel
Journal:  Iran J Basic Med Sci       Date:  2017-08       Impact factor: 2.699

9.  Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Authors:  Jan Lewerenz; Paul Baxter; Rebecca Kassubek; Philipp Albrecht; Joeri Van Liefferinge; Mike-Andrew Westhoff; Marc-Eric Halatsch; Georg Karpel-Massler; Paul J Meakin; John D Hayes; Eleonora Aronica; Ilse Smolders; Albert C Ludolph; Axel Methner; Marcus Conrad; Ann Massie; Giles E Hardingham; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

10.  Age-associated expression of erythropoietin and its receptor in rat spiral ganglion neurons and its association with neuronal apoptosis and hearing alterations.

Authors:  Cheng Zhong; Xueyuan Zhang
Journal:  Mol Med Rep       Date:  2016-12-09       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.